PortalPublikationenDoes Pregnenolone Enhance Exposure Therapy in Obsessive-Comp...

Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study

Standard

Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study. / Kellner, M; Nowack, S ; Wortmann, V; Yassouridis, A; Wiedemann, K.

in: PHARMACOPSYCHIATRY, Jahrgang 49, Nr. 2, 03.2016, S. 79-81.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Kellner, M, Nowack, S, Wortmann, V, Yassouridis, A & Wiedemann, K 2016, 'Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study', PHARMACOPSYCHIATRY, Jg. 49, Nr. 2, S. 79-81. https://doi.org/10.1055/s-0035-1569371

APA

Kellner, M., Nowack, S., Wortmann, V., Yassouridis, A., & Wiedemann, K. (2016). Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study. PHARMACOPSYCHIATRY, 49(2), 79-81. https://doi.org/10.1055/s-0035-1569371

Vancouver

Kellner M, Nowack S, Wortmann V, Yassouridis A, Wiedemann K. Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study. PHARMACOPSYCHIATRY. 2016 Mär;49(2):79-81. https://doi.org/10.1055/s-0035-1569371

Bibtex

@article{ab884863c28e452e89b5af43c6d652da,
title = "Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study",
abstract = "Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABAA receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.",
keywords = "Adult, Combined Modality Therapy, Double-Blind Method, Humans, Implosive Therapy, Male, Neurotransmitter Agents, Obsessive-Compulsive Disorder, Pilot Projects, Pregnenolone, Treatment Outcome, Letter, Randomized Controlled Trial",
author = "M Kellner and S Nowack and V Wortmann and A Yassouridis and K Wiedemann",
note = "Document Type:Letter",
year = "2016",
month = mar,
doi = "10.1055/s-0035-1569371",
language = "English",
volume = "49",
pages = "79--81",
journal = "PHARMACOPSYCHIATRY",
issn = "0176-3679",
publisher = "Georg Thieme Verlag KG",
number = "2",

}

RIS

TY - JOUR

T1 - Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study

AU - Kellner, M

AU - Nowack, S

AU - Wortmann, V

AU - Yassouridis, A

AU - Wiedemann, K

N1 - Document Type:Letter

PY - 2016/3

Y1 - 2016/3

N2 - Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABAA receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.

AB - Exposure therapy is an effective cognitive-behavioral treatment for patients with obsessive-compulsive disorder (OCD). However, a further amelioration of symptoms by additional drugs that enhance extinction learning is desirable. An interesting candidate is pregnenolone, which positively modulates NMDA and GABAA receptors in preclinical studies and influences amygdala and prefrontal activity in humans. We present pilot data showing high acceptance and good tolerability of pregnenolone given 2 h before exposure sessions in OCD patients. As per our interim analyses, exposure treatment resulted in significantly improved main outcome parameters, but no effects of pregnenolone vs. placebo pretreatment were detectable thus far.

KW - Adult

KW - Combined Modality Therapy

KW - Double-Blind Method

KW - Humans

KW - Implosive Therapy

KW - Male

KW - Neurotransmitter Agents

KW - Obsessive-Compulsive Disorder

KW - Pilot Projects

KW - Pregnenolone

KW - Treatment Outcome

KW - Letter

KW - Randomized Controlled Trial

U2 - 10.1055/s-0035-1569371

DO - 10.1055/s-0035-1569371

M3 - Other (editorial matter etc.)

C2 - 26797931

VL - 49

SP - 79

EP - 81

JO - PHARMACOPSYCHIATRY

JF - PHARMACOPSYCHIATRY

SN - 0176-3679

IS - 2

ER -